Country Access Report
Denmark does not offer routine medical access to classical psychedelics. Psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, ibogaine and related substances remain controlled and are accessible only through authorised research or special permissions. Esketamine is the meaningful current access route: Medicinraadet now recommends Spravato for a defined treatment-resistant depression subgroup and for acute suicidal-risk care, but treatment remains specialist and supervised.
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Psilocybin and psilocin, including psilocybin-containing mushrooms and spores, are controlled on Denmark's List B. Lawful access outside ordinary prescription medicine is limited to authorised scientific or medical use; current Danish psilocybin activity is research, including alcohol use disorder, cluster headache and PsyPal. [1] [2] [3] [4] [5]
Compound Access
Compound Access
Spravato is EU-authorised. In November 2025 Medicinraadet recommended it for adults with moderate-to-severe treatment-resistant depression after at least three failed antidepressant treatments in the current episode; it had already been recommended for admitted patients with acute suicidal risk. Delivery still requires supervised clinical use and defined start-stop criteria. [1] [2] [3] [4]
Compound Access
Compound Access
DMT is controlled on Denmark's List B. No authorised routine medical or reimbursement route was identified in reviewed sources. [1]
Compound Access
5-MeO-DMT is controlled on Denmark's List B. Reviewed sources did not show a Danish patient-access or reimbursement route. [1]
Compound Access
Ibogaine is controlled on Denmark's List B. No routine treatment or reimbursement pathway was identified. [1]
Compound Access
Compound Access
Mescaline is controlled on Denmark's List B. No routine medical or reimbursement route was identified. [1]
Compound Access
Last updated 14 May 2026. Source links come from the medical access guide.